Logo

American Heart Association

  2
  0


Final ID: MDP874

Association of Sociodemographic Characteristics on Costs of Care in Patients with Obstructive Hypertrophic Cardiomyopathy

Abstract Body (Do not enter title and authors here): Introduction: No evidence exists on the impact of sociodemographic characteristics on costs of care for obstructive hypertrophic cardiomyopathy (oHCM). Therefore, we evaluated 5-year cumulative costs by age, sex, and race/ethnicity.
Methods: Retrospective cohort study of adults diagnosed with oHCM (January 2013 to December 2021) using Optum claims and electronic medical record data. Patients with ≥2 claims for HCM (ICD-9 and-10) at least 30 days apart (index date = earliest oHCM claim) with ≥1 additional oHCM claim or septal reduction therapy, 6-months pre-index and 5-year post-index continuous enrollment were included. HCM-related cumulative costs (2022 CPI adjusted) were reported for medical (ambulatory [AB]: office [OV] visits, outpatient [OP] visits); emergency room [ER] visits; inpatient admissions (IP); and pharmacy (Rx).
Results: Among 5,129 patients with oHCM, 52% were female (mean age 63.9 ± 14.3 years; 77.6% non-Hispanic White; 40% Medicare). Compared to females (Table), male patients had greater costs including total ($71,581 vs $63,710, p= 0.014), medical ($70,395 vs $62,455, p= 0.013), ambulatory ($16,024 vs $10,776, p<0.001), OV ($1,906 vs $1,573, p<0.001), and OP ($14,118 vs $9,202, p<0.001). Compared with White patients, Black patients had significantly greater IP costs ($54,572 vs $42,686, p= 0.01), Hispanic patients had greater ER costs ($1,724 vs $791, p<0.001), and Asian patients had greater OV costs ($2,094 vs $1,800, p<0.001). Patients aged 18-39 years had greater costs across all categories (p<0.001; IP=NS), except Rx. Patients aged 40-54 years had the highest Rx costs ($1,557, p<0.001), followed by 18-39, 55-64, 65-74, 75+ years ($1,528; $1,329; $1,197; $867), respectively.
Conclusions: For oHCM patients, being male and age 18-39 years was associated with increased HCM-related healthcare costs. Differences in cost across race/ethnicity exist, including greater IP and ER costs for Black and Hispanic patients, respectively. Future research is required to understand the source of these differences among oHCM patients.
  • Reza, Nosheen  ( Perelman School of Medicine at the University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Butzner, Michael  ( Cytokinetics, Inc. , South San Francisco , California , United States )
  • Batra, Kirti  ( Optum , Eden Prarie , Minnesota , United States )
  • Amos, Qiana  ( Optum , Eden Prarie , Minnesota , United States )
  • Buikema, Ami  ( Optum , Eden Prarie , Minnesota , United States )
  • Anderson, Amy  ( Optum , Eden Prarie , Minnesota , United States )
  • Shreay, Sanatan  ( Cytokinetics, Inc. , South San Francisco , California , United States )
  • Owens, Anjali  ( Perelman School of Medicine at the University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Author Disclosures:
    Nosheen Reza: DO have relevant financial relationships ; Advisor:American Regent:Past (completed) ; Advisor:Bristol Myers Squibb:Past (completed) ; Research Funding (PI or named investigator):Bristol Myers Squibb:Active (exists now) ; Advisor:Roche Diagnostics:Past (completed) ; Speaker:Zoll:Past (completed) | Michael Butzner: DO have relevant financial relationships ; Employee:Cytokinetics, Inc.:Active (exists now) ; Individual Stocks/Stock Options:Cytokinetics, Inc.:Active (exists now) | Kirti Batra: DO NOT have relevant financial relationships | Qiana Amos: No Answer | Ami Buikema: DO have relevant financial relationships ; Employee:Optum:Active (exists now) ; Other (please indicate in the box next to the company name):Cytokinetics - Contracted with Optum to conduct the research:Active (exists now) | Amy Anderson: No Answer | Sanatan Shreay: No Answer | Anjali Owens: DO have relevant financial relationships ; Consultant:BMS:Active (exists now) ; Consultant:corvista:Active (exists now) ; Consultant:stealth:Active (exists now) ; Consultant:Edgewise:Active (exists now) ; Consultant:Alexion:Active (exists now) ; Consultant:Lexicon:Active (exists now) ; Consultant:Lexeo:Active (exists now) ; Consultant:Tenaya:Active (exists now) ; Consultant:biomarin:Active (exists now) ; Consultant:Cytokinetics:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Socioeconomic Insights and Innovations in Heart Failure

Sunday, 11/17/2024 , 09:30AM - 10:55AM

Moderated Digital Poster Session

More abstracts on this topic:
A New Small-Molecule ErbB4 Agonist Attenuates Adverse Ventricular Remodeling After Myocardial Infarction In a Sex-Specific Manner

Goovaerts Bo, Civati Celine, Feyen Eline, De Keulenaer Gilles, Segers Vincent

Costs and Healthcare Resource Utilization in Transthyretin Amyloid Cardiomyopathy Exceeds That of Non-amyloid Heart Failure

Grodin Justin, Sanghi Shradha, Dev Sandesh, Nativi-nicolau Jose, Masri Ahmad, Wright Richard, Tamby Jean-francois, Falvey Heather, Hennum Liana, Badwe Chaitanya, Allison Melissa, Ramesh Rakesh

More abstracts from these authors:
Panelist

Chatfield Kathryn, Owens Anjali

A Fungus Among Us

Reza Nosheen, Breathett Khadijah, Mclean Rhondalyn

You have to be authorized to contact abstract author. Please, Login
Not Available